Synapse - Vincent Miller

Results (270)

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

Meeting Abstract

Kabbinavar, F. F.; Miller, V. A.; Johnson, B. E.; O'Connor, P. G.; Soh, C.; for the ATLAS Investigators
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer

Journal Article

Sequist, L. V.; Besse, B.; Lynch, T. J.; Miller, V. A.; Wong, K. K.; Gitlitz, B.; Eaton, K.; Zacharchuk, C.; Freyman, A.; Powell, C; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

Journal Article

Janjigian, Y. Y.; Lee, W.; Kris, M. G.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Senturk, E.; Calcutt, M. W.; Rizvi, N. A.
Cancer Chemotherapy and Pharmacology (2010)

Fulltext@MSK | Save

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Journal Article

Jackman, D.; Pao, W.; Riely, G. J.; Engelman, J. A.; Kris, M. G.; Jänne, P. A.; Lynch, T.; Johnson, B. E.; Miller, V. A.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Selective pressure for the EGFR T790M resistance mutation may be different for different EGFR tyrosine kinase inhibitors

Meeting Abstract

Chmielecki, J.; Pietanza, M. C.; Kris, M.; Miller, V.; Pao, W.
Journal of Thoracic Oncology (2010)

Fulltext@MSK | Save

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

Journal Article

Price, K. A.; Azzoli, C. G.; Krug, L. M.; Pietanza, M. C.; Rizvi, N. A.; Pao, W.; Kris, M. G.; Riely, G. J.; Heelan, R. T.; Arcila, M. E.; more...
Journal of Thoracic Oncology (2010)

Fulltext@MSK | Save

Use of erlotinib or gefitinib as initial therapy in advanced NSCLC

Journal Article

Oxnard, G. R.; Miller, V. A.
Oncology (Norwalk) (2010)

Fulltext@MSK | Save

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-and erlotinib-resistant adenocarcinoma of the lung

Journal Article

Leighl, N. B.; Raez, L. E.; Besse, B.; Rosen, P. J.; Barlesi, F.; Massarelli, E.; Gabrail, N.; Hart, L. L.; Albain, K. S.; Berkowitz, L.; more...
Journal of Thoracic Oncology (2010)

Fulltext@MSK | Save

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

Journal Article

Haura, E. B.; Ricart, A. D.; Larson, T. G.; Stella, P. J.; Bazhenova, L.; Miller, V. A.; Cohen, R. B.; Eisenberg, P. D.; Selaru, P.; Wilner, K. D.; more...
Clinical Cancer Research (2010)

Fulltext@MSK | Save

Analysis of genetic variants in never-smokers with lung cancer facilitated by an internet-based blood collection protocol: A preliminary report

Journal Article

Girard, N.; Lou, E.; Azzoli, C. G.; Reddy, R.; Robson, M.; Harlan, M.; Orlow, I.; Yatabe, Y.; Nafa, K.; Ladanyi, M.; more...
Clinical Cancer Research (2010)

Fulltext@MSK | Save